Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diuretic Use in Hemodialysis Patients With Residual Renal Function
NCT05915286Phase 4Terminated
- Sponsor
- University of Alberta
- Start
- May 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of furosemide, chlorthalidone in end stage renal disease (ESRD), sponsored by University of Alberta. Started May 2023; status: terminated.
02
Drugs
furosemidechlorthalidone
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT05915286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05915286.